CD38 and acute myeloid leukemia: We observed positive selection of aberrant HSPC subpopulations with weak/negative expression of CD38 (on CD34+) and/or HLADR– a finding in ~45% of this high-risk AML cohort by the metric of >10-fold relative expansion within the blast compartment in the months preceding relapse.